ES2146192T1 - Metodo y composiciones para modular la sensibilidad a los corticosteroides. - Google Patents
Metodo y composiciones para modular la sensibilidad a los corticosteroides.Info
- Publication number
- ES2146192T1 ES2146192T1 ES98912929T ES98912929T ES2146192T1 ES 2146192 T1 ES2146192 T1 ES 2146192T1 ES 98912929 T ES98912929 T ES 98912929T ES 98912929 T ES98912929 T ES 98912929T ES 2146192 T1 ES2146192 T1 ES 2146192T1
- Authority
- ES
- Spain
- Prior art keywords
- agent
- corticosteroid
- subject
- inhibitor
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a un procedimiento para modular la sensibilidad a los corticoesteroides en un sujeto. Conforme a este procedimiento, se administra a dicho sujeto un agente que se opone a una diana que regula la producción de IFN-{ga}, así como un corticoesteroide de manera que la sensibilidad del sujeto al corticoesteroide se modula en comparación con lo que es cuando el corticoesteroides se administra solo. Según una realización, dicho agente es un antagonista de IL-8. Según otra realización, dicho agente es un antagonista de la interleuquina-12 (IL-12). Según otra realización más, el agente es un antagonista de las células NJ. Según una realización preferente, el agente es un inhibidor de una proteasa de la familia de las caspasas, preferentemente un inhibidor de la enzima de conversión de la interleuquina -1''beta'' (ICE). En otras realizaciones preferentes, el agente es un anticuerpo monoclonal anti-IL-12 o un anticuerpo anti-asialo-GM1 o un anticuerpo MK1.1. Otros agentes preferentes comprenden los inhibidores de fosfodiesterasa IV y beta-2 agonistas. Los procedimientos de esta invenciones revelan útiles para el tratamiento de una pluralidad de enfermedades y trastornos inflamatorios e inmunológicos. Esta invención se refiere también a composiciones farmacéuticas que comprenden un agente que se opone a una diana que regula la producción de IFN-''gamma'' en un sujeto, a un corticoesteroide y a un excipiente farmacéuticamente aceptable. Una composición comprende un inhibidor de ICE, un corticoesteroide y un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/820,692 US6054487A (en) | 1997-03-18 | 1997-03-18 | Methods and compositions for modulating responsiveness to corticosteroids |
US1634698A | 1998-01-30 | 1998-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2146192T1 true ES2146192T1 (es) | 2000-08-01 |
Family
ID=26688484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98912929T Pending ES2146192T1 (es) | 1997-03-18 | 1998-03-12 | Metodo y composiciones para modular la sensibilidad a los corticosteroides. |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0998300A1 (es) |
JP (1) | JP2002504091A (es) |
KR (1) | KR20000076420A (es) |
CN (1) | CN1269722A (es) |
AU (1) | AU734756B2 (es) |
BG (1) | BG103808A (es) |
BR (1) | BR9810409A (es) |
CA (1) | CA2282845A1 (es) |
DE (1) | DE998300T1 (es) |
ES (1) | ES2146192T1 (es) |
HU (1) | HUP0104439A3 (es) |
ID (1) | ID22975A (es) |
IL (1) | IL131815A0 (es) |
NO (1) | NO994506L (es) |
NZ (1) | NZ337769A (es) |
PL (1) | PL336464A1 (es) |
SI (1) | SI20110A (es) |
SK (1) | SK122199A3 (es) |
TR (1) | TR199902615T2 (es) |
WO (1) | WO1998041232A2 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
AR015966A1 (es) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
EP1516630A3 (en) * | 1997-10-31 | 2006-05-03 | Wyeth | Use of anti-il-12 antibodies in transplantation rejection |
CA2276420A1 (en) * | 1997-10-31 | 1999-05-14 | Terry Strom | Use of anti-il-12 antibodies in transplantation rejection |
WO1999025737A1 (en) * | 1997-11-19 | 1999-05-27 | Tanox Pharma B.V. | Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain |
ATE295177T1 (de) * | 1998-03-16 | 2005-05-15 | Cytovia Inc | Dipeptid kaspase inhibitoren und deren verwendung |
EP1140206A4 (en) * | 1998-11-27 | 2002-04-10 | Technion Res & Dev Foundation | VACCINE BASED ON INTERFERON GAMMA INDUCTION FACTOR AND USE THEREOF FOR PROVIDING PROTECTION IMMUNITY AGAINST MULTIPLE SCLEROSIS |
EP1336654A1 (en) * | 1998-12-09 | 2003-08-20 | Protein Design Labs, Inc. | Method of treating psoriasis using anti-gamma interferon antibody |
EP1165490B1 (en) | 1999-03-16 | 2006-08-16 | Cytovia, Inc. | Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
DE19915465A1 (de) * | 1999-04-06 | 2000-10-19 | Apotech Res & Dev Ltd | Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten |
ATE363465T1 (de) | 1999-04-09 | 2007-06-15 | Cytovia Inc | Caspase inhibitoren und ihre verwendung |
IL131047A0 (en) * | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
EA200200301A1 (ru) | 1999-08-27 | 2002-08-29 | Сайтовиэ, Инк. | ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ |
WO2001019373A2 (en) * | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
AU2001236807A1 (en) | 2000-02-10 | 2001-08-20 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
WO2001093909A2 (en) * | 2000-06-06 | 2001-12-13 | Glaxo Group Limited | Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
AU7250301A (en) * | 2000-06-22 | 2002-01-02 | Willy Ben Moussa Ben Mohammed | Use of glucocorticosteroids for producing a medicament to treat oligotrichia |
US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
WO2002022127A1 (en) * | 2000-09-13 | 2002-03-21 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
EP1188438A1 (en) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
EE05534B1 (et) * | 2001-01-29 | 2012-04-16 | Applied Research Systems Ars Holding N.V. | IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks |
DK1425028T3 (da) * | 2001-05-16 | 2010-03-01 | Yeda Res & Dev | Anvendelse af IL-18 inhibitorer til behandling eller forebyggelse af sepsis |
ATE464068T1 (de) | 2001-06-26 | 2010-04-15 | Amgen Fremont Inc | Antikörper gegen opgl |
WO2003030823A2 (en) * | 2001-10-05 | 2003-04-17 | Combinatorx, Incorporated | Combinations for the treatment of immunoinflammatory disorders |
JP2003342196A (ja) * | 2002-05-31 | 2003-12-03 | Mukku:Kk | 静脈注射用組成物、その製造法およびその製剤 |
AR041386A1 (es) * | 2002-09-24 | 2005-05-18 | Combinatorx Inc | Metodos y reactivos para el tratamiento de enfermedades y trastornos asociados con niveles aumentados de citoquinas proinflamatorias |
WO2004028545A1 (en) * | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
US20060083714A1 (en) * | 2003-01-27 | 2006-04-20 | Warner James M | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
EP1752159A4 (en) * | 2004-05-17 | 2009-07-01 | Univ Keio | MEDICAL COMPOSITION AND THERAPEUTIC PROCEDURE |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DK1808446T3 (da) * | 2004-07-16 | 2012-05-14 | Atsuo Sekiyama | IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten |
CA2584169A1 (en) * | 2004-10-13 | 2006-04-20 | Kyowa Hakko Kogyo Co., Ltd. | Remedies/preventives for chronic skin disease |
ES2384641T3 (es) | 2005-07-14 | 2012-07-10 | Lithera, Inc. | Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo |
JP2010506941A (ja) * | 2006-10-17 | 2010-03-04 | リセラ,インク. | 甲状腺眼症の治療のための方法、組成物及び製剤 |
CN104524567A (zh) | 2007-01-16 | 2015-04-22 | 阿布维公司 | 用于治疗银屑病的方法 |
WO2008121301A1 (en) | 2007-03-29 | 2008-10-09 | Abbott Laboratories | Crystalline anti-human il-12 antibodies |
KR20100126515A (ko) | 2008-03-18 | 2010-12-01 | 아보트 러보러터리즈 | 건선의 치료방법 |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
EA201270784A1 (ru) | 2010-11-24 | 2013-04-30 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Монотерапевтические композиции селективного липофильного и бета-агониста длительного действия и способы косметического лечения ожирения и контурного выпячивания |
WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
AU2022353032A1 (en) * | 2021-09-22 | 2024-03-28 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
GB2235626B (en) * | 1989-09-08 | 1994-02-09 | Glaxo Group Ltd | Inhalation medicaments for treating respiratory disorders |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
MX9304585A (es) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. |
GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
JP3573213B2 (ja) * | 1995-04-14 | 2004-10-06 | グラクソ、ウェルカム、インコーポレーテッド | ベクロメタゾンジプロピオネート用計量投与用吸入器 |
-
1998
- 1998-03-12 KR KR1019997008524A patent/KR20000076420A/ko not_active Application Discontinuation
- 1998-03-12 EP EP98912929A patent/EP0998300A1/en not_active Withdrawn
- 1998-03-12 PL PL98336464A patent/PL336464A1/xx unknown
- 1998-03-12 AU AU67604/98A patent/AU734756B2/en not_active Ceased
- 1998-03-12 CA CA002282845A patent/CA2282845A1/en not_active Abandoned
- 1998-03-12 DE DE0998300T patent/DE998300T1/de active Pending
- 1998-03-12 JP JP54063398A patent/JP2002504091A/ja active Pending
- 1998-03-12 IL IL13181598A patent/IL131815A0/xx unknown
- 1998-03-12 ES ES98912929T patent/ES2146192T1/es active Pending
- 1998-03-12 SI SI9820032A patent/SI20110A/sl unknown
- 1998-03-12 NZ NZ337769A patent/NZ337769A/xx unknown
- 1998-03-12 TR TR1999/02615T patent/TR199902615T2/xx unknown
- 1998-03-12 BR BR9810409-8A patent/BR9810409A/pt not_active IP Right Cessation
- 1998-03-12 WO PCT/US1998/004916 patent/WO1998041232A2/en not_active Application Discontinuation
- 1998-03-12 CN CN98805124A patent/CN1269722A/zh active Pending
- 1998-03-12 HU HU0104439A patent/HUP0104439A3/hu unknown
- 1998-03-12 ID IDW991185A patent/ID22975A/id unknown
- 1998-03-12 SK SK1221-99A patent/SK122199A3/sk unknown
-
1999
- 1999-09-17 NO NO994506A patent/NO994506L/no unknown
- 1999-10-13 BG BG103808A patent/BG103808A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2282845A1 (en) | 1998-09-24 |
KR20000076420A (ko) | 2000-12-26 |
HUP0104439A2 (hu) | 2002-04-29 |
BR9810409A (pt) | 2000-08-22 |
PL336464A1 (en) | 2000-06-19 |
NO994506D0 (no) | 1999-09-17 |
EP0998300A1 (en) | 2000-05-10 |
BG103808A (en) | 2000-07-31 |
CN1269722A (zh) | 2000-10-11 |
TR199902615T2 (xx) | 2000-03-21 |
AU734756B2 (en) | 2001-06-21 |
NO994506L (no) | 1999-11-17 |
AU6760498A (en) | 1998-10-12 |
NZ337769A (en) | 2002-09-27 |
WO1998041232A2 (en) | 1998-09-24 |
IL131815A0 (en) | 2001-03-19 |
HUP0104439A3 (en) | 2002-08-28 |
ID22975A (id) | 1999-12-23 |
WO1998041232A3 (en) | 2000-10-05 |
SK122199A3 (en) | 2000-12-11 |
DE998300T1 (de) | 2001-03-01 |
SI20110A (sl) | 2000-06-30 |
JP2002504091A (ja) | 2002-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2146192T1 (es) | Metodo y composiciones para modular la sensibilidad a los corticosteroides. | |
AR025669A1 (es) | Metodos y composiciones para la modulacion de la capacidad de respuesta a los corticosteroides. | |
Hayami et al. | The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model | |
Clark et al. | The measurement of collagenase, tissue inhibitor of metalloproteinases (timp), and collagenase—timp complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis | |
Thompson Jr | An experimental study of surface injury to articular cartilage and enzyme responses within the joint. | |
Elliott et al. | The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders | |
Buckley et al. | Mast cell subpopulations in the synovial tissue of patients with osteoarthritis: selective increase in numbers of tryptase‐positive, chymase‐negative mast cells | |
NO982185L (no) | Nye makrosykliske forbindelser som metalloproteinaseinhibitorer | |
NO20092860L (no) | 2, 6 dioksopiperidin samt farmasoytiske preparater som inneholder disse | |
Woessner Jr | Purification of cathepsin D from cartilage and uterus and its action on the protein-polysaccharide complex of cartilage | |
EHRLICH et al. | Biochemical and physiological events during closure of the stapled distal femoral epiphyseal plate in rats | |
ATE310019T1 (de) | Citrullin-enthaltende fibrin-derivate und ihre verwendung zur diagnose und behandlung von rheumatischer arthritis | |
Szomor et al. | Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice. | |
Fassbender et al. | Synovial processes in rheumatoid arthritis | |
Kawahara et al. | The 26 S proteasome is activated at two points in the ascidian cell cycle | |
Lovász et al. | Cartilage changes caused by a coronal surface stepoff in a rabbit model | |
Zardeneta et al. | Detection and preliminary characterization of matrix metalloproteinase activity in temporomandibular joint lavage fluid | |
Tanaka et al. | Joint Degradation in a Monkey Model of Collagen‐Induced Arthritis: Role of Cathepsin K Based on Biochemical Markers and Histological Evaluation | |
PT1100483E (pt) | Agentes anti-inflamatorios selectivos para glicocorticoide | |
NO963497L (no) | Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel | |
Mainardi | The role of connective tissue degrading enzymes in human pathology | |
Koraćević et al. | Effect of trypsin, S-adenosylmethionine and ethionine on L-serine sulfhydrase activity | |
Van de Lest et al. | Loading‐induced changes in synovial fluid affect cartilage metabolism | |
Fu et al. | Erythropoietin enhances meniscal regeneration and prevents osteoarthritis formation in mice | |
Schalkwijk et al. | Effects of experimental joint inflammation on bone marrow and periarticular bone. A study of two types of arthritis, using variable degrees of inflammation. |